6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Tendon	NNP	tendon	tendon	tendon	N	B-AdverseReaction
ruptures	NNS	ruptures	rupture	ruptur	N	I-AdverseReaction
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
injury	NN	injury	injury	injuri	Y	B-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction

rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
penile	NN	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

In	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
ecchymoses	NNS	ecchymoses	ecchymosis	ecchymos	Y	I-AdverseReaction
or	CC	or	or	or	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
sudden	JJ	sudden	sudden	sudden	N	O
penile	NN	penile	penile	penil	N	B-AdverseReaction
detumescence	NN	detumescence	detumescence	detumesc	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
"	NN	"	"	"	N	I-AdverseReaction
popping	VBG	popping	popping	pop	N	I-AdverseReaction
"	JJ	"	"	"	N	I-AdverseReaction
sound	NN	sound	sound	sound	N	I-AdverseReaction
or	CC	or	or	or	N	O
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
cannot	NN	cannot	cannot	cannot	N	B-Factor
be	VB	be	be	be	N	I-Factor
excluded	VBN	excluded	excluded	exclud	N	I-Factor
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
Contracture	NNP	contracture	contracture	contractur	Y	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
25%	CD	25%	25%	25%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
edema	JJ	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
swelling	VBG	swelling	swelling	swell	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
hand	NN	hand	hand	hand	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
.	.	.	.	.	N	O

Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
Disease	NNP	disease	disease	diseas	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
with	IN	with	with	with	N	O
25%	CD	25%	25%	25%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
penile	IN	penile	penile	penil	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
and	CC	and	and	and	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Auxilium	NNP	auxilium	auxilium	auxilium	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
663	CD	663	663	663	N	O
-	:	-	-	-	N	O
0412	CD	0412	0412	0412	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
Contracture	NN	contracture	contracture	contractur	Y	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
1082	CD	1082	1082	1082	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
2630	CD	2630	2630	2630	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
flexor	JJ	flexor	flexor	flexor	N	B-AdverseReaction
tendon	JJ	tendon	tendon	tendon	N	I-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
treated	JJ	treated	treated	treat	N	O
finger	NN	finger	finger	finger	N	I-AdverseReaction
within	IN	within	within	within	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
two	CD	two	two	two	N	O
pooled	JJ	pooled	pooled	pool	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
90	CD	90	90	90	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
with	IN	with	with	with	N	O
approximately	RB	approximately	approximately	approxim	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
intervals	NNS	intervals	interval	interv	N	O
between	IN	between	between	between	N	O
injections	NNS	injections	injection	inject	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
finger	VBN	finger	finger	finger	N	O
extension	NN	extension	extension	extens	N	O
procedures	VBZ	procedures	procedure	procedur	N	O
the	DT	the	the	the	N	O
day	NN	day	day	day	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
needed	VBN	needed	needed	need	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
facilitate	VB	facilitate	facilitate	facilit	N	O
disruption	NN	disruption	disruption	disrupt	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
cord	NN	cord	cord	cord	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
comprised	VBN	comprised	comprised	compris	N	O
of	IN	of	of	of	N	O
374	CD	374	374	374	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
249	CD	249	249	249	N	O
and	CC	and	and	and	N	O
125	CD	125	125	125	N	O
received	VBD	received	received	receiv	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
63	CD	63	63	63	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
80%	CD	80%	80%	80%	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
and	CC	and	and	and	N	O
20%	CD	20%	20%	20%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
100%	CD	100%	100%	100%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
90	CD	90	90	90	N	O
,	,	,	,	,	N	O
98%	CD	98%	98%	98%	N	O
and	CC	and	and	and	N	O
51%	CD	51%	51%	51%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
and	CC	and	and	and	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
after	IN	after	after	after	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
injections	NNS	injections	injection	inject	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Over	IN	over	over	over	N	O
95%	CD	95%	95%	95%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
after	IN	after	after	after	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
81%	CD	81%	81%	81%	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
local	JJ	local	local	local	N	O
reactions	NNS	reactions	reaction	reaction	N	O
resolved	VBD	resolved	resolved	resolv	N	O
without	IN	without	without	without	N	O
intervention	NN	intervention	intervention	intervent	N	O
within	IN	within	within	within	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
profile	NN	profile	profile	profil	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
each	DT	each	each	each	N	O
injection	NN	injection	injection	inject	Y	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
injections	NNS	injections	injection	inject	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
increased	VBN	increased	increased	increas	N	O
with	IN	with	with	with	N	O
more	RBR	more	more	more	N	O
injections	NNS	injections	injection	inject	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
included	VBD	included	included	includ	N	O
edema	JJ	edema	edema	edema	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
(	(	(	(	(	N	O
mostly	RB	mostly	mostly	mostli	N	O
swelling	VBG	swelling	swelling	swell	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
hand	NN	hand	hand	hand	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
treated	JJ	treated	treated	treat	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
after	IN	after	after	after	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
90	CD	90	90	90	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
Contracture	NN	contracture	contracture	contractur	Y	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Greater	NNP	greater	greater	greater	N	O
Incidence	NNP	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
Through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
90	CD	90	90	90	N	O
After	IN	after	after	after	N	O
Up	NNP	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
Injections	NNS	injections	injection	inject	N	O

a	DT	a	a	a	N	O
Most	NNP	most	most	most	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
swelling	VBG	swelling	swelling	swell	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
hand	NN	hand	hand	hand	N	I-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
(	(	(	(	(	N	O
any	DT	any	any	ani	N	O
body	NN	body	body	bodi	N	O
system	NN	system	system	system	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
ecchymosis	NN	ecchymosis	ecchymosis	ecchymosi	Y	B-AdverseReaction

c	SYM	c	c	c	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
irritation	NN	irritation	irritation	irrit	N	I-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
warmth	NN	warmth	warmth	warmth	N	I-AdverseReaction

d	NN	d	d	d	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction

e	NN	e	e	e	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction

f	NN	f	f	f	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
lymphadenopathy	NN	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
axillary	JJ	axillary	axillary	axillari	N	B-AdverseReaction
mass	NN	mass	mass	mass	Y	I-AdverseReaction

Adverse	NN	adverse	adverse	advers	N	O

Reaction	NNP	reaction	reaction	reaction	N	O
XIAFLEXN	NNP	xiaflexn	xiaflexn	xiaflexn	N	O
249	CD	249	249	249	N	O
PlaceboN	NNP	placebon	placebon	placebon	N	O
125	CD	125	125	125	N	O

All	DT	all	all	all	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
98%	CD	98%	98%	98%	N	O
51%	CD	51%	51%	51%	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
Peripheral	NNP	peripheral	peripheral	peripher	N	I-AdverseReaction
a	DT	a	a	a	N	O
73%	CD	73%	73%	73%	N	O
5%	CD	5%	5%	5%	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
b	VBD	b	b	b	N	O
70%	CD	70%	70%	70%	N	O
3%	CD	3%	3%	3%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
Site	NNP	site	site	site	N	I-AdverseReaction
Hemorrhage	NNP	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
38%	CD	38%	38%	38%	N	O
3%	CD	3%	3%	3%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
Site	NNP	site	site	site	N	I-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
c	VBD	c	c	c	N	O
35%	CD	35%	35%	35%	N	O
6%	CD	6%	6%	6%	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Extremity	NNP	extremity	extremity	extrem	N	I-AdverseReaction
35%	CD	35%	35%	35%	N	O
4%	CD	4%	4%	4%	N	O

Tenderness	RB	tenderness	tenderness	tender	Y	B-AdverseReaction
24%	CD	24%	24%	24%	N	O
0%	CD	0%	0%	0%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
Site	NNP	site	site	site	N	I-AdverseReaction
Swelling	NNP	swelling	swelling	swell	Y	I-AdverseReaction
d	VBD	d	d	d	N	O
24%	CD	24%	24%	24%	N	O
6%	CD	6%	6%	6%	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
e	VBD	e	e	e	N	O
15%	CD	15%	15%	15%	N	O
1%	CD	1%	1%	1%	N	O

Lymphadenopathy	NNP	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
f	VBD	f	f	f	N	O
13%	CD	13%	13%	13%	N	O
0%	CD	0%	0%	0%	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
Laceration	NNP	laceration	laceration	lacer	Y	I-AdverseReaction
9%	CD	9%	9%	9%	N	O
0%	CD	0%	0%	0%	N	O

Lymph	NNP	lymph	lymph	lymph	N	B-AdverseReaction
Node	NNP	node	node	node	N	I-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
8%	CD	8%	8%	8%	N	O
0%	CD	0%	0%	0%	N	O

Erythema	NNP	erythema	erythema	erythema	Y	B-AdverseReaction
6%	CD	6%	6%	6%	N	O
0%	CD	0%	0%	0%	N	O

Axillary	NNP	axillary	axillary	axillari	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
6%	CD	6%	6%	6%	N	O
0%	CD	0%	0%	0%	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
vasovagal	JJ	vasovagal	vasovagal	vasovag	N	B-AdverseReaction
syncope	NN	syncope	syncope	syncop	Y	I-AdverseReaction
after	IN	after	after	after	N	O
finger	JJR	finger	finger	finger	N	O
extension	NN	extension	extension	extens	N	O
procedures	NNS	procedures	procedure	procedur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
two	CD	two	two	two	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
into	IN	into	into	into	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
cords	NNS	cords	cord	cord	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
hand	NN	hand	hand	hand	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
historically	RB	historically	historically	histor	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
multi	SYM	multi	multi	multi	N	O
-	:	-	-	-	N	O
center	NN	center	center	center	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
715	CD	715	715	715	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
finger	JJR	finger	finger	finger	N	O
extension	NN	extension	extension	extens	N	O
procedures	NNS	procedures	procedure	procedur	N	O
were	VBD	were	were	were	N	O
performed	VBN	performed	performed	perform	N	O
approximately	RB	approximately	approximately	approxim	N	O
24	CD	24	24	24	N	O
to	TO	to	to	to	N	O
72	CD	72	72	72	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
demographics	NNS	demographics	demographic	demograph	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
Studies	VB	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
715	CD	715	715	715	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
two	CD	two	two	two	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
hand	NN	hand	hand	hand	N	O
(	(	(	(	(	N	O
1450	CD	1450	1450	1450	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
patient	NN	patient	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
tendon	JJ	tendon	tendon	tendon	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
treated	JJ	treated	treated	treat	N	O
finger	NN	finger	finger	finger	N	I-AdverseReaction
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
after	IN	after	after	after	N	O
two	CD	two	two	two	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
hand	NN	hand	hand	hand	N	O
through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
60	CD	60	60	60	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
Who	NNP	who	who	who	N	O
Received	VBD	received	received	receiv	N	O
Two	CD	two	two	two	N	O
Concurrent	NNP	concurrent	concurrent	concurr	N	O
Injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
XIAFLEXN	NNP	xiaflexn	xiaflexn	xiaflexn	N	O
715	CD	715	715	715	N	O

Subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
1	CD	1	1	1	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
95%	CD	95%	95%	95%	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
77%	CD	77%	77%	77%	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
59%	CD	59%	59%	59%	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
51%	CD	51%	51%	51%	N	O

Laceration	NN	laceration	laceration	lacer	Y	B-AdverseReaction
22%	CD	22%	22%	22%	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
15%	CD	15%	15%	15%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14%	CD	14%	14%	14%	N	O

Lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
13%	CD	13%	13%	13%	N	O

Blood	NNP	blood	blood	blood	N	B-AdverseReaction
blister	NN	blister	blister	blister	Y	I-AdverseReaction
12%	CD	12%	12%	12%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
8%	CD	8%	8%	8%	N	O

Axillary	NNP	axillary	axillary	axillari	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
7%	CD	7%	7%	7%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
6%	CD	6%	6%	6%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
5%	CD	5%	5%	5%	N	O

Ecchymosis	NN	ecchymosis	ecchymosis	ecchymosi	Y	B-AdverseReaction
5%	CD	5%	5%	5%	N	O

Safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
Retreatment	NNP	retreatment	retreatment	retreat	N	O
of	IN	of	of	of	N	O
Recurrent	NNP	recurrent	recurrent	recurr	N	O
Contractures	NNP	contractures	contracture	contractur	N	O

An	DT	an	an	an	N	O

observational	JJ	observational	observational	observ	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
label	NN	label	label	label	N	O
study	NN	study	study	studi	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
participated	VBN	participated	participated	particip	N	O
in	IN	in	in	in	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
subset	NN	subset	subset	subset	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
contracture	NN	contracture	contracture	contractur	Y	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
joint	JJ	joint	joint	joint	N	O
that	WDT	that	that	that	N	O
was	VBD	was	wa	wa	N	O
previously	RB	previously	previously	previous	N	O
successfully	RB	successfully	successfully	success	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
4	CD	4	4	4	N	O
were	VBD	were	were	were	N	O
retreated	VBN	retreated	retreated	retreat	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
new	JJ	new	new	new	N	O
safety	NN	safety	safety	safeti	N	O
signals	NNS	signals	signal	signal	N	O
were	VBD	were	were	were	N	O
identified	VBN	identified	identified	identifi	N	O
among	IN	among	among	among	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
retreated	VBN	retreated	retreated	retreat	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
Disease	NNP	disease	disease	diseas	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
1044	CD	1044	1044	1044	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
7466	CD	7466	7466	7466	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

Corporal	JJ	corporal	corporal	corpor	N	O
Rupture	NNP	rupture	rupture	ruptur	N	O
and	CC	and	and	and	N	O
Other	JJ	other	other	other	N	O
Serious	NNP	serious	serious	seriou	N	O
Penile	NNP	penile	penile	penil	N	O
Injury	NNP	injury	injury	injuri	Y	O

Corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
after	IN	after	after	after	N	O
XIAFLEX	JJ	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
;	:	;	;	;	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
ecchymoses	NNS	ecchymoses	ecchymosis	ecchymos	Y	I-AdverseReaction
or	CC	or	or	or	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
sudden	JJ	sudden	sudden	sudden	N	O
penile	NN	penile	penile	penil	N	B-AdverseReaction
detumescence	NN	detumescence	detumescence	detumesc	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
"	NN	"	"	"	N	I-AdverseReaction
popping	VBG	popping	popping	pop	N	I-AdverseReaction
"	JJ	"	"	"	N	I-AdverseReaction
sound	NN	sound	sound	sound	N	I-AdverseReaction
or	CC	or	or	or	N	O
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
cannot	NN	cannot	cannot	cannot	N	B-Factor
be	VB	be	be	be	N	I-Factor
excluded	VBN	excluded	excluded	exclud	N	I-Factor
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
managed	VBN	managed	managed	manag	N	O
without	IN	without	without	without	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
penile	NN	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
39	CD	39	39	39	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
two	CD	two	two	two	N	O
identical	JJ	identical	identical	ident	N	O
,	,	,	,	,	N	O
pooled	VBD	pooled	pooled	pool	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
multi	SYM	multi	multi	multi	N	O
-	:	-	-	-	N	O
center	NN	center	center	center	N	O
trials	NNS	trials	trial	trial	N	O
through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
365	CD	365	365	365	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
832	CD	832	832	832	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
551	CD	551	551	551	N	O
and	CC	and	and	and	N	O
281	CD	281	281	281	N	O
received	VBN	received	received	receiv	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
given	VBN	given	given	given	N	O
up	RP	up	up	up	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycles	NNS	cycles	cycle	cycl	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
each	DT	each	each	each	N	O
cycle	NN	cycle	cycle	cycl	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
or	CC	or	or	or	N	O
two	CD	two	two	two	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
administered	VBN	administered	administered	administ	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
apart	RB	apart	apart	apart	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
penile	NN	penile	penile	penil	N	O
modeling	VBG	modeling	modeling	model	N	O
procedure	NN	procedure	procedure	procedur	N	O
was	VBD	was	wa	wa	N	O
performed	VBN	performed	performed	perform	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
site	NN	site	site	site	N	O
on	IN	on	on	on	N	O
patients	NNS	patients	patient	patient	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
cycle	NN	cycle	cycle	cycl	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycle	NN	cycle	cycle	cycl	N	O
was	VBD	was	wa	wa	N	O
repeated	VBN	repeated	repeated	repeat	N	O
at	IN	at	at	at	N	O
approximately	RB	approximately	approximately	approxim	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
intervals	NNS	intervals	interval	interv	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
three	CD	three	three	three	N	O
additional	JJ	additional	additional	addit	N	O
times	NNS	times	time	time	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
maximum	NN	maximum	maximum	maximum	N	O
of	IN	of	of	of	N	O
8	CD	8	8	8	N	O
total	JJ	total	total	total	N	O
injection	NN	injection	injection	inject	Y	O
procedures	NNS	procedures	procedure	procedur	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
total	JJ	total	total	total	N	O
modeling	NN	modeling	modeling	model	N	O
procedures	NNS	procedures	procedure	procedur	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
92%	CD	92%	92%	92%	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
61%	CD	61%	61%	61%	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
local	JJ	local	local	local	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
penis	NN	penis	penis	peni	N	I-AdverseReaction
and	CC	and	and	and	N	O
groin	NN	groin	groin	groin	N	I-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
of	IN	of	of	of	N	O
mild	NN	mild	mild	mild	N	B-Severity
or	CC	or	or	or	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
most	JJS	most	most	most	N	O
(	(	(	(	(	N	O
79%	CD	79%	79%	79%	N	O
)	)	)	)	)	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
14	CD	14	14	14	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
profile	NN	profile	profile	profil	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
after	IN	after	after	after	N	O
each	DT	each	each	each	N	O
injection	NN	injection	injection	inject	Y	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
injections	NNS	injections	injection	inject	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
were	VBD	were	were	were	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
penile	IN	penile	penile	penil	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
penile	RB	penile	penile	penil	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
after	IN	after	after	after	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
8	CD	8	8	8	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
through	IN	through	through	through	N	O
Day	NNP	day	day	day	N	O
365	CD	365	365	365	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Greater	NNP	greater	greater	greater	N	O
Incidence	NNP	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
After	IN	after	after	after	N	O
Up	NNP	up	up	up	N	O
to	TO	to	to	to	N	O
Four	CD	four	four	four	N	O
Treatment	NN	treatment	treatment	treatment	N	O
Cycles	NNP	cycles	cycle	cycl	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
Combined	VBD	combined	combined	combin	N	O

a	DT	a	a	a	N	O
Includes	NNS	includes	includes	includ	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
and	CC	and	and	and	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
verbatim	JJ	verbatim	verbatim	verbatim	N	O
term	NN	term	term	term	N	O
of	IN	of	of	of	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
bruising	NN	bruising	bruising	bruis	Y	I-AdverseReaction
or	CC	or	or	or	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
bruising	NN	bruising	bruising	bruis	Y	I-AdverseReaction
in	IN	in	in	in	N	O
87%	CD	87%	87%	87%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Includes	NNS	includes	includes	includ	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
penile	IN	penile	penile	penil	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
local	JJ	local	local	local	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
scrotal	JJ	scrotal	scrotal	scrotal	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
.	.	.	.	.	N	O

c	SYM	c	c	c	N	O
Includes	NNS	includes	includes	includ	N	O
:	:	:	:	:	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
penile	NN	penile	penile	penil	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
.	.	.	.	.	N	O

d	NN	d	d	d	N	O
Includes	NNS	includes	includes	includ	N	O
:	:	:	:	:	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
,	,	,	,	,	N	O
ecchymoses	VBZ	ecchymoses	ecchymosis	ecchymos	Y	B-AdverseReaction
,	,	,	,	,	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

Reaction	NNP	reaction	reaction	reaction	N	O
XIAFLEXN	NNP	xiaflexn	xiaflexn	xiaflexn	N	O
551	CD	551	551	551	N	O
PlaceboN	NNP	placebon	placebon	placebon	N	O
281	CD	281	281	281	N	O

All	DT	all	all	all	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
84.2%	CD	84.2%	84.2%	84.2%	N	O
36.3%	CD	36.3%	36.3%	36.3%	N	O

Penile	NNP	penile	penile	penil	N	B-AdverseReaction
hematoma	VBD	hematoma	hematoma	hematoma	Y	I-AdverseReaction
a	DT	a	a	a	N	O
65.5%	CD	65.5%	65.5%	65.5%	N	O
19.2%	CD	19.2%	19.2%	19.2%	N	O

Penile	NNP	penile	penile	penil	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
b	NN	b	b	b	N	O
55.0%	CD	55.0%	55.0%	55.0%	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O

Penile	NNP	penile	penile	penil	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
c	VBD	c	c	c	N	O
45.4%	CD	45.4%	45.4%	45.4%	N	O
9.3%	CD	9.3%	9.3%	9.3%	N	O

Penile	NNP	penile	penile	penil	N	B-AdverseReaction
ecchymoses	VBZ	ecchymoses	ecchymosis	ecchymos	Y	I-AdverseReaction
d	VBP	d	d	d	N	O
14.5%	CD	14.5%	14.5%	14.5%	N	O
6.8%	CD	6.8%	6.8%	6.8%	N	O

Blood	NNP	blood	blood	blood	N	B-AdverseReaction
blister	NN	blister	blister	blister	Y	I-AdverseReaction
4.5%	CD	4.5%	4.5%	4.5%	N	O
0	CD	0	0	0	N	O

Penile	NNP	penile	penile	penil	N	B-AdverseReaction
blister	NN	blister	blister	blister	Y	I-AdverseReaction
3.3%	CD	3.3%	3.3%	3.3%	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
3.1%	CD	3.1%	3.1%	3.1%	N	O
0	CD	0	0	0	N	O

Painful	JJ	painful	painful	pain	N	B-AdverseReaction
erection	NN	erection	erection	erect	N	I-AdverseReaction
2.9%	CD	2.9%	2.9%	2.9%	N	O
0	CD	0	0	0	N	O

Erectile	NNP	erectile	erectile	erectil	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
1.8%	CD	1.8%	1.8%	1.8%	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
1.8%	CD	1.8%	1.8%	1.8%	N	O
0	CD	0	0	0	N	O

Procedural	NNP	procedural	procedural	procedur	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1.6%	CD	1.6%	1.6%	1.6%	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
vesicles	NNS	vesicles	vesicle	vesicl	Y	I-AdverseReaction
1.3%	CD	1.3%	1.3%	1.3%	N	O
0	CD	0	0	0	N	O

Localized	VBN	localized	localized	local	N	B-AdverseReaction
edema	RB	edema	edema	edema	Y	I-AdverseReaction
1.3%	CD	1.3%	1.3%	1.3%	N	O
0	CD	0	0	0	N	O

Dyspareunia	NNP	dyspareunia	dyspareunia	dyspareunia	Y	B-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
0	CD	0	0	0	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
0	CD	0	0	0	N	O

Nodule	NNP	nodule	nodule	nodul	Y	B-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
0	CD	0	0	0	N	O

Suprapubic	NNP	suprapubic	suprapubic	suprapub	N	B-AdverseReaction
pain	VBP	pain	pain	pain	Y	I-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
0	CD	0	0	0	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
penile	NN	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	B-Severity
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
33	CD	33	33	33	N	O
551	CD	551	551	551	N	O
(	(	(	(	(	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0	CD	0	0	0	N	O
281	CD	281	281	281	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
combined	VBN	combined	combined	combin	N	O
.	.	.	.	.	N	O

Reports	NNS	reports	report	report	N	O

of	IN	of	of	of	N	O
penile	JJ	penile	penile	penil	N	O
"	NNP	"	"	"	N	O
popping	VBG	popping	popping	pop	N	O
"	JJ	"	"	"	N	O
sounds	NNS	sounds	sound	sound	N	O
or	CC	or	or	or	N	O
sensations	NNS	sensations	sensation	sensat	N	O
A	VBP	a	a	a	N	O
popping	VBG	popping	popping	pop	N	B-AdverseReaction
noise	NN	noise	noise	nois	N	I-AdverseReaction
or	CC	or	or	or	N	O
popping	VBG	popping	popping	pop	N	B-AdverseReaction
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
penis	NN	penis	penis	peni	N	I-AdverseReaction
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
described	VBN	described	described	describ	N	O
as	IN	as	a	as	N	O
"	JJ	"	"	"	N	O
snapping	VBG	snapping	snapping	snap	N	I-AdverseReaction
"	NN	"	"	"	N	O
or	CC	or	or	or	N	O
"	VB	"	"	"	N	O
cracking	VBG	cracking	cracking	crack	N	I-AdverseReaction
"	NNP	"	"	"	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
detumescence	NN	detumescence	detumescence	detumesc	N	B-AdverseReaction
,	,	,	,	,	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
73	CD	73	73	73	N	O
551	CD	551	551	551	N	O
(	(	(	(	(	N	O
13.2%	CD	13.2%	13.2%	13.2%	N	O
)	)	)	)	)	N	O
XIAFLEX	SYM	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
281	CD	281	281	281	N	O
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
)	)	)	)	)	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
clinically	RB	clinically	clinically	clinic	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
following	VBG	following	following	follow	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
baseline	NN	baseline	baseline	baselin	N	O
erectile	JJ	erectile	erectile	erectil	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
or	CC	or	or	or	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
phosphodiesterase	NN	phosphodiesterase	phosphodiesterase	phosphodiesteras	N	O
type	NN	type	type	type	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
)	)	)	)	)	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	B-Negation
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
shortening	NN	shortening	shortening	shorten	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
penile	JJ	penile	penile	penil	N	I-AdverseReaction
length	NN	length	length	length	N	I-AdverseReaction
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

During	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
and	CC	and	and	and	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
tested	VBN	tested	tested	test	N	O
at	IN	at	at	at	N	O
multiple	JJ	multiple	multiple	multipl	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
protein	NN	protein	protein	protein	Y	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
(	(	(	(	(	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NN	ii	ii	ii	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
post	VBD	post	post	post	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
XIAFLEX	$	xiaflex	xiaflex	xiaflex	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
92%	CD	92%	92%	92%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
detected	VBD	detected	detected	detect	N	O
and	CC	and	and	and	N	O
86%	CD	86%	86%	86%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NNP	ii	ii	ii	N	O
detected	VBD	detected	detected	detect	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
the	DT	the	the	the	N	O
fourth	JJ	fourth	fourth	fourth	N	O
injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patient	JJ	patient	patient	patient	N	O
developed	JJ	developed	developed	develop	N	O
high	JJ	high	high	high	N	O
titers	NNS	titers	titer	titer	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
both	DT	both	both	both	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NNP	ii	ii	ii	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
five	CD	five	five	five	N	O
years	NNS	years	year	year	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
90	CD	90	90	90	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
remained	VBD	remained	remained	remain	N	O
seropositive	JJ	seropositive	seropositive	seroposit	N	O
for	IN	for	for	for	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NNP	ii	ii	ii	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
assayed	VBN	assayed	assayed	assay	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
204	CD	204	204	204	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
or	CC	or	or	or	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NN	ii	ii	ii	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
21%	CD	21%	21%	21%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
no	DT	no	no	no	N	O
prior	JJ	prior	prior	prior	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
,	,	,	,	,	N	O
97%	CD	97%	97%	97%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NN	ii	ii	ii	N	O
after	IN	after	after	after	N	O
two	CD	two	two	two	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
total	JJ	total	total	total	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1.16	CD	1.16	1.16	1.16	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
hand	NN	hand	hand	hand	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
5	CD	5	5	5	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
recurrent	NN	recurrent	recurrent	recurr	N	O
contractures	NNS	contractures	contracture	contractur	N	O
with	IN	with	with	with	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
similar	JJ	similar	similar	similar	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
results	NNS	results	result	result	N	O
as	IN	as	a	as	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycle	NN	cycle	cycle	cycl	N	O
of	IN	of	of	of	N	O
XIAFLEX	$	xiaflex	xiaflex	xiaflex	N	O
0.58	CD	0.58	0.58	0.58	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
75%	CD	75%	75%	75%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
approximately	RB	approximately	approximately	approxim	N	O
55%	CD	55%	55%	55%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NNP	ii	ii	ii	N	O
.	.	.	.	.	N	O

Six	NNP	six	six	six	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
eighth	JJ	eighth	eighth	eighth	N	O
injection	NN	injection	injection	inject	Y	O
(	(	(	(	(	N	O
fourth	JJ	fourth	fourth	fourth	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycle	NN	cycle	cycle	cycl	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
,	,	,	,	,	N	O
99%	CD	99%	99%	99%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
developed	JJ	developed	developed	develop	N	O
high	JJ	high	high	high	N	O
titers	NNS	titers	titer	titer	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
both	DT	both	both	both	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NNP	ii	ii	ii	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
assayed	VBN	assayed	assayed	assay	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
subset	NN	subset	subset	subset	N	O
of	IN	of	of	of	N	O
70	CD	70	70	70	N	O
samples	NNS	samples	sample	sampl	N	O
selected	VBN	selected	selected	select	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
representative	JJ	representative	representative	repres	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
and	CC	and	and	and	N	O
low	JJ	low	low	low	N	O
titer	NN	titer	titer	titer	N	O
binding	VBG	binding	binding	bind	N	O
antibody	NN	antibody	antibody	antibodi	N	O
responses	NNS	responses	response	respons	N	O
at	IN	at	at	at	N	O
week	NN	week	week	week	N	O
12	CD	12	12	12	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
each	DT	each	each	each	N	O
subject	NN	subject	subject	subject	N	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
a	DT	a	a	a	N	O
Week	JJ	week	week	week	N	O
12	CD	12	12	12	N	O
sample	NN	sample	sample	sampl	N	O
was	VBD	was	wa	wa	N	O
selected	VBN	selected	selected	select	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
corresponding	JJ	corresponding	corresponding	correspond	N	O
Week	NNP	week	week	week	N	O
6	CD	6	6	6	N	O
,	,	,	,	,	N	O
18	CD	18	18	18	N	O
,	,	,	,	,	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
52	CD	52	52	52	N	O
samples	NNS	samples	sample	sampl	N	O
were	VBD	were	were	were	N	O
assayed	VBN	assayed	assayed	assay	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
binding	VBG	binding	binding	bind	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positive	JJ	positive	positive	posit	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
or	CC	or	or	or	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NN	ii	ii	ii	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
in	IN	in	in	in	N	O
60%	CD	60%	60%	60%	N	O
and	CC	and	and	and	N	O
51.8%	CD	51.8%	51.8%	51.8%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBN	tested	tested	test	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
two	CD	two	two	two	N	O
indications	NNS	indications	indication	indic	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
apparent	JJ	apparent	apparent	appar	N	O
correlation	NN	correlation	correlation	correl	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
frequency	NN	frequency	frequency	frequenc	N	O
,	,	,	,	,	N	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
status	NN	status	status	statu	N	O
to	TO	to	to	to	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
or	CC	or	or	or	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
the	DT	the	the	the	N	O
protein	NN	protein	protein	protein	Y	O
components	NNS	components	component	compon	N	O
in	IN	in	in	in	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
(	(	(	(	(	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
I	PRP	i	i	i	N	O
and	CC	and	and	and	N	O
AUX	NNP	aux	aux	aux	N	O
-	:	-	-	-	N	O
II	NN	ii	ii	ii	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
some	DT	some	some	some	N	O
sequence	NN	sequence	sequence	sequenc	N	O
homology	NN	homology	homology	homolog	N	O
with	IN	with	with	with	N	O
human	JJ	human	human	human	N	O
matrix	NN	matrix	matrix	matrix	N	O
metalloproteinases	NNS	metalloproteinases	metalloproteinases	metalloproteinas	N	O
(	(	(	(	(	N	O
MMPs	NNP	mmps	mmps	mmp	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
product	NN	product	product	product	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
could	MD	could	could	could	N	O
theoretically	RB	theoretically	theoretically	theoret	N	O
interfere	VB	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
human	JJ	human	human	human	N	O
MMPs	NNP	mmps	mmps	mmp	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
vitro	JJ	vitro	vitro	vitro	N	O
studies	NNS	studies	study	studi	N	O
showed	VBD	showed	showed	show	N	O
no	DT	no	no	no	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
cross	NN	cross	cross	cross	N	O
-	:	-	-	-	N	O
reactivity	NN	reactivity	reactivity	reactiv	N	O
between	IN	between	between	between	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
antibody	NN	antibody	antibody	antibodi	N	O
positive	JJ	positive	positive	posit	N	O
patient	NN	patient	patient	patient	N	O
sera	NN	sera	serum	sera	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
series	NN	series	series	seri	N	O
of	IN	of	of	of	N	O
relevant	JJ	relevant	relevant	relev	N	O
MMPs	NNP	mmps	mmps	mmp	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
safety	NN	safety	safety	safeti	N	O
concerns	NNS	concerns	concern	concern	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
endogenous	JJ	endogenous	endogenous	endogen	N	O
MMPs	NNP	mmps	mmps	mmp	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Immunogenicity	NNP	immunogenicity	immunogenicity	immunogen	N	O
assay	VBP	assay	assay	assay	N	O
results	NNS	results	result	result	N	O
are	VBP	are	are	are	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
detection	NN	detection	detection	detect	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
collagenase	VB	collagenase	collagenase	collagenas	N	O
clostridium	NN	clostridium	clostridium	clostridium	N	O
histolyticum	NN	histolyticum	histolyticum	histolyticum	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
CORPORAL	NNP	corporal	corporal	corpor	N	B-AdverseReaction
RUPTURE	NNP	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
PENILE	NNP	penile	penile	penil	N	B-AdverseReaction
FRACTURE	NNP	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
OR	NNP	or	or	or	N	O
\n\n	VBZ	\n\n	\n\n	\n\n	N	O
OTHER	NNP	other	other	other	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
PENILE	NNP	penile	penile	penil	N	B-AdverseReaction
INJURY	NNP	injury	injury	injuri	Y	I-AdverseReaction
IN	NNP	in	in	in	N	O
THE	NNP	the	the	the	N	O
TREATMENT	NNP	treatment	treatment	treatment	N	O
OF	NNP	of	of	of	N	O
PEYRONIE	NNP	peyronie	peyronie	peyroni	N	O
S	NNP	s	s	s	N	O
DISEASE	NNP	disease	disease	diseas	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
CORPORAL	NNP	corporal	corporal	corpor	N	B-AdverseReaction
RUPTURE	NNP	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
PENILE	NNP	penile	penile	penil	N	B-AdverseReaction
FRACTURE	NNP	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
OR	NNP	or	or	or	N	O
\n\n	VBZ	\n\n	\n\n	\n\n	N	O
OTHER	NNP	other	other	other	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
PENILE	NNP	penile	penile	penil	N	B-AdverseReaction
INJURY	NNP	injury	injury	injuri	Y	I-AdverseReaction
IN	NNP	in	in	in	N	O
THE	NNP	the	the	the	N	O
TREATMENT	NNP	treatment	treatment	treatment	N	O
OF	NNP	of	of	of	N	O
PEYRONIE	NNP	peyronie	peyronie	peyroni	N	O
S	NNP	s	s	s	N	O
DISEASE	NNP	disease	disease	diseas	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Corporal	NNP	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
XIAFLEX	SYM	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
;	:	;	;	;	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
ecchymoses	NNS	ecchymoses	ecchymosis	ecchymos	Y	I-AdverseReaction
or	CC	or	or	or	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
sudden	JJ	sudden	sudden	sudden	N	O
penile	NN	penile	penile	penil	N	B-AdverseReaction
detumescence	NN	detumescence	detumescence	detumesc	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
"	NN	"	"	"	N	I-AdverseReaction
popping	VBG	popping	popping	pop	N	I-AdverseReaction
"	JJ	"	"	"	N	I-AdverseReaction
sound	NN	sound	sound	sound	N	I-AdverseReaction
or	CC	or	or	or	N	O
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
cannot	NN	cannot	cannot	cannot	N	B-Factor
be	VB	be	be	be	N	I-Factor
excluded	VBN	excluded	excluded	exclud	N	I-Factor
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
penile	NN	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
39	CD	39	39	39	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
(	(	(	(	(	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
)	)	)	)	)	N	O
XIAFLEX	SYM	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
reflect	VB	reflect	reflect	reflect	N	O
serious	JJ	serious	serious	seriou	N	O
penile	JJ	penile	penile	penil	N	O
injury	NN	injury	injury	injuri	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
promptly	RB	promptly	promptly	promptli	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
for	IN	for	for	for	N	O
corporal	JJ	corporal	corporal	corpor	N	O
rupture	NN	rupture	rupture	ruptur	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
penile	NN	penile	penile	penil	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
penile	JJ	penile	penile	penil	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
,	,	,	,	,	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
is	VBZ	is	is	is	N	O
available	JJ	available	available	avail	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
only	RB	only	only	onli	N	O
through	IN	through	through	through	N	O
a	DT	a	a	a	N	O
restricted	VBN	restricted	restricted	restrict	N	O
program	NN	program	program	program	N	O
under	IN	under	under	under	N	O
a	DT	a	a	a	N	O
Risk	NNP	risk	risk	risk	N	O
Evaluation	NNP	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
Mitigation	NNP	mitigation	mitigation	mitig	N	O
Strategy	NNP	strategy	strategy	strategi	N	O
(	(	(	(	(	N	O
REMS	NNP	rems	rem	rem	N	O
)	)	)	)	)	N	O
called	VBD	called	called	call	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
REMS	NNP	rems	rem	rem	N	O
Program	NNP	program	program	program	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CORPORAL	JJ	corporal	corporal	corpor	N	B-AdverseReaction
RUPTURE	NNP	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
PENILE	NNP	penile	penile	penil	N	B-AdverseReaction
FRACTURE	NNP	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
OR	NNP	or	or	or	N	O
OTHER	NNP	other	other	other	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
PENILE	NNP	penile	penile	penil	N	B-AdverseReaction
INJURY	NNP	injury	injury	injuri	Y	I-AdverseReaction
IN	NNP	in	in	in	N	O
THE	NNP	the	the	the	N	O
TREATMENT	NNP	treatment	treatment	treatment	N	O
OF	NNP	of	of	of	N	O
PEYRONIE	NNP	peyronie	peyronie	peyroni	N	O
S	NNP	s	s	s	N	O
DISEASE	NNP	disease	disease	diseas	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Corporal	NNP	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
XIAFLEX	SYM	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
;	:	;	;	;	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
cannot	NN	cannot	cannot	cannot	N	B-Factor
be	VB	be	be	be	N	I-Factor
excluded	VBN	excluded	excluded	exclud	N	I-Factor
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
penile	NN	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
39	CD	39	39	39	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
(	(	(	(	(	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
)	)	)	)	)	N	O
XIAFLEX	SYM	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
is	VBZ	is	is	is	N	O
available	JJ	available	available	avail	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
only	RB	only	only	onli	N	O
through	IN	through	through	through	N	O
a	DT	a	a	a	N	O
restricted	VBN	restricted	restricted	restrict	N	O
program	NN	program	program	program	N	O
called	VBN	called	called	call	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
REMS	NNP	rems	rem	rem	N	O
Program	NNP	program	program	program	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Tendon	JJ	tendon	tendon	tendon	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
injury	NN	injury	injury	injuri	Y	B-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
injected	JJ	injected	injected	inject	N	I-AdverseReaction
finger	NN	finger	finger	finger	N	I-AdverseReaction
hand	NN	hand	hand	hand	N	I-AdverseReaction
:	:	:	:	:	N	O
Avoid	NNP	avoid	avoid	avoid	N	O
injecting	VBG	injecting	injecting	inject	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
into	IN	into	into	into	N	O
tendons	NNS	tendons	tendon	tendon	N	O
,	,	,	,	,	N	O
nerves	NNS	nerves	nerve	nerv	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
vessels	NNS	vessels	vessel	vessel	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
collagen	NN	collagen	collagen	collagen	N	O
-	:	-	-	-	N	O
containing	NN	containing	containing	contain	N	O
structure	NN	structure	structure	structur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
hand	NN	hand	hand	hand	N	O
.	.	.	.	.	N	O

Injection	NN	injection	injection	inject	Y	O
into	IN	into	into	into	N	O
these	DT	these	these	these	N	O
structures	NNS	structures	structure	structur	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
possible	JJ	possible	possible	possibl	N	O
permanent	JJ	permanent	permanent	perman	N	O
injury	NN	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
tendon	JJ	tendon	tendon	tendon	N	O
rupture	NN	rupture	rupture	ruptur	N	O
or	CC	or	or	or	N	O
ligament	JJ	ligament	ligament	ligament	N	O
damage	NN	damage	damage	damag	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
skin	JJ	skin	skin	skin	N	O
laceration	NN	laceration	laceration	lacer	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
injury	NN	injury	injury	injuri	Y	B-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
penis	NN	penis	penis	peni	N	I-AdverseReaction
:	:	:	:	:	N	O
Avoid	JJ	avoid	avoid	avoid	N	O
injecting	VBG	injecting	injecting	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
urethra	NN	urethra	urethra	urethra	N	O
,	,	,	,	,	N	O
nerves	NNS	nerves	nerve	nerv	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
vessels	NNS	vessels	vessel	vessel	N	O
,	,	,	,	,	N	O
corpora	NNS	corpora	corpus	corpora	N	O
cavernosa	VBP	cavernosa	cavernosa	cavernosa	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
collagen	NN	collagen	collagen	collagen	N	O
-	:	-	-	-	N	O
containing	VBG	containing	containing	contain	N	O
structures	NNS	structures	structure	structur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
penis	NN	penis	penis	peni	N	O
.	.	.	.	.	N	O

Injection	NN	injection	injection	inject	Y	O
into	IN	into	into	into	N	O
these	DT	these	these	these	N	O
structures	NNS	structures	structure	structur	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
possible	JJ	possible	possible	possibl	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
:	:	:	:	:	N	O
Healthcare	JJ	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
prepared	VBN	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
address	VB	address	address	address	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
following	VBG	following	following	follow	N	O
XIAFLEX	JJ	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
coagulation	NN	coagulation	coagulation	coagul	N	O
:	:	:	:	:	N	O
Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
received	VBN	received	received	receiv	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
medications	NNS	medications	medication	medic	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
aspirin	NN	aspirin	aspirin	aspirin	N	O
within	IN	within	within	within	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
injection	NN	injection	injection	inject	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Tendon	NN	tendon	tendon	tendon	N	O

Rupture	NN	rupture	rupture	ruptur	N	O
or	CC	or	or	or	N	O
Other	JJ	other	other	other	N	O
Serious	JJ	serious	serious	seriou	N	O
Injury	NNP	injury	injury	injuri	Y	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
Injected	NNP	injected	injected	inject	N	O
Finger	NNP	finger	finger	finger	N	O
Hand	NNP	hand	hand	hand	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
Contracture	NN	contracture	contracture	contractur	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
,	,	,	,	,	N	O
flexor	JJ	flexor	flexor	flexor	N	B-AdverseReaction
tendon	NN	tendon	tendon	tendon	N	I-AdverseReaction
ruptures	NNS	ruptures	rupture	ruptur	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
injection	NN	injection	injection	inject	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
into	IN	into	into	into	N	O
collagen	NN	collagen	collagen	collagen	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
containing	VBG	containing	containing	contain	N	I-AdverseReaction
structures	NNS	structures	structure	structur	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
tendons	NNS	tendons	tendon	tendon	N	B-AdverseReaction
or	CC	or	or	or	N	O
ligaments	NNS	ligaments	ligament	ligament	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
hand	NN	hand	hand	hand	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
damage	NN	damage	damage	damag	N	I-AdverseReaction
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
structures	NNS	structures	structure	structur	N	O
and	CC	and	and	and	N	O
possible	JJ	possible	possible	possibl	N	B-Factor
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
tendon	JJ	tendon	tendon	tendon	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
or	CC	or	or	or	N	O
ligament	JJ	ligament	ligament	ligament	N	B-AdverseReaction
damage	NN	damage	damage	damag	N	I-AdverseReaction
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
injected	VBN	injected	injected	inject	N	O
only	RB	only	only	onli	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
collagen	NN	collagen	collagen	collagen	N	O
cord	NN	cord	cord	cord	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
MP	NNP	mp	mp	mp	N	O
or	CC	or	or	or	N	O
PIP	NNP	pip	pip	pip	N	O
joint	JJ	joint	joint	joint	N	O
contracture	NN	contracture	contracture	contractur	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
injecting	VBG	injecting	injecting	inject	N	O
into	IN	into	into	into	N	O
tendons	NNS	tendons	tendon	tendon	N	O
,	,	,	,	,	N	O
nerves	NNS	nerves	nerve	nerv	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
vessels	NNS	vessels	vessel	vessel	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
collagen	NN	collagen	collagen	collagen	N	O
-	:	-	-	-	N	O
containing	VBG	containing	containing	contain	N	O
structures	NNS	structures	structure	structur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
hand	NN	hand	hand	hand	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
injecting	VBG	injecting	injecting	inject	N	O
a	DT	a	a	a	N	O
cord	NN	cord	cord	cord	N	O
affecting	VBG	affecting	affecting	affect	N	O
a	DT	a	a	a	N	O
PIP	NNP	pip	pip	pip	N	O
joint	NN	joint	joint	joint	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
fifth	JJ	fifth	fifth	fifth	N	O
finger	NN	finger	finger	finger	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
needle	JJ	needle	needle	needl	N	O
insertion	NN	insertion	insertion	insert	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
mm	NNS	mm	mm	mm	N	O
in	IN	in	in	in	N	O
depth	NN	depth	depth	depth	N	O
and	CC	and	and	and	N	O
avoid	VB	avoid	avoid	avoid	N	O
injecting	VBG	injecting	injecting	inject	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
4	CD	4	4	4	N	O
mm	JJ	mm	mm	mm	N	O
distal	NN	distal	distal	distal	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
palmar	NN	palmar	palmar	palmar	N	O
digital	JJ	digital	digital	digit	N	O
crease	NN	crease	crease	creas	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
serious	JJ	serious	serious	seriou	N	O
local	JJ	local	local	local	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
included	VBD	included	included	includ	N	O
pulley	JJ	pulley	pulley	pulley	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
,	,	,	,	,	N	O
ligament	JJ	ligament	ligament	ligament	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
,	,	,	,	,	N	O
complex	JJ	complex	complex	complex	N	B-AdverseReaction
regional	JJ	regional	regional	region	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
CRPS	NNP	crps	crp	crp	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
sensory	JJ	sensory	sensory	sensori	N	B-AdverseReaction
abnormality	NN	abnormality	abnormality	abnorm	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
hand	NN	hand	hand	hand	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
laceration	NN	laceration	laceration	lacer	Y	I-AdverseReaction
(	(	(	(	(	N	O
tear	JJ	tear	tear	tear	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
historically	RB	historically	historically	histor	N	O
controlled	VBN	controlled	controlled	control	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
laceration	NN	laceration	laceration	lacer	Y	I-AdverseReaction
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
higher	JJR	higher	higher	higher	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
two	CD	two	two	two	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
injections	NNS	injections	injection	inject	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
three	CD	three	three	three	N	O
single	JJ	single	single	singl	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
premarketing	NN	premarketing	premarketing	premarket	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
laceration	NN	laceration	laceration	lacer	Y	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
skin	NN	skin	skin	skin	N	O
graft	NN	graft	graft	graft	N	O
after	IN	after	after	after	N	O
finger	JJR	finger	finger	finger	N	O
extension	NN	extension	extension	extens	N	O
procedures	NNS	procedures	procedure	procedur	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
.	.	.	.	.	N	O

Signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
reflect	VB	reflect	reflect	reflect	N	O
serious	JJ	serious	serious	seriou	N	O
injury	NN	injury	injury	injuri	Y	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
injected	JJ	injected	injected	inject	N	O
finger	NN	finger	finger	finger	N	O
hand	NN	hand	hand	hand	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
promptly	RB	promptly	promptly	promptli	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
because	RB	because	because	becaus	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Corporal	JJ	corporal	corporal	corpor	N	O
Rupture	NNP	rupture	rupture	ruptur	N	O
(	(	(	(	(	N	O
Penile	NNP	penile	penile	penil	N	O
Fracture	NNP	fracture	fracture	fractur	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
Other	JJ	other	other	other	N	O
Serious	JJ	serious	serious	seriou	N	O
Injury	NNP	injury	injury	injuri	Y	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
Penis	NNP	penis	penis	peni	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
Disease	NNP	disease	disease	diseas	N	O

Corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
after	IN	after	after	after	N	O
XIAFLEX	JJ	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
;	:	;	;	;	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
ecchymoses	NNS	ecchymoses	ecchymosis	ecchymos	Y	I-AdverseReaction
or	CC	or	or	or	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
sudden	JJ	sudden	sudden	sudden	N	O
penile	NN	penile	penile	penil	N	B-AdverseReaction
detumescence	NN	detumescence	detumescence	detumesc	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
"	NN	"	"	"	N	I-AdverseReaction
popping	VBG	popping	popping	pop	N	I-AdverseReaction
"	JJ	"	"	"	N	I-AdverseReaction
sound	NN	sound	sound	sound	N	I-AdverseReaction
or	CC	or	or	or	N	O
sensation	NN	sensation	sensation	sensat	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
not	RB	not	not	not	N	I-Factor
be	VB	be	be	be	N	I-Factor
excluded	VBN	excluded	excluded	exclud	N	I-Factor
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
managed	VBN	managed	managed	manag	N	O
without	IN	without	without	without	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
penile	NN	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
39	CD	39	39	39	N	O
of	IN	of	of	of	N	O
1044	CD	1044	1044	1044	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
reflect	VB	reflect	reflect	reflect	N	O
serious	JJ	serious	serious	seriou	N	O
injury	NN	injury	injury	injuri	Y	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
penis	NN	penis	penis	peni	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
promptly	RB	promptly	promptly	promptli	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
for	IN	for	for	for	N	O
corporal	JJ	corporal	corporal	corpor	N	O
rupture	NN	rupture	rupture	ruptur	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
penile	NN	penile	penile	penil	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

Injection	NN	injection	injection	inject	Y	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
into	IN	into	into	into	N	O
collagen	NN	collagen	collagen	collagen	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
containing	VBG	containing	containing	contain	N	I-AdverseReaction
structures	NNS	structures	structure	structur	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
corpora	NN	corpora	corpus	corpora	N	B-AdverseReaction
cavernosa	NN	cavernosa	cavernosa	cavernosa	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
penis	NN	penis	penis	peni	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
damage	NN	damage	damage	damag	N	I-AdverseReaction
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
structures	NNS	structures	structure	structur	N	O
and	CC	and	and	and	N	O
possible	JJ	possible	possible	possibl	N	B-Factor
injury	NN	injury	injury	injuri	Y	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
corporal	JJ	corporal	corporal	corpor	N	B-AdverseReaction
rupture	NN	rupture	rupture	ruptur	N	I-AdverseReaction
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
injected	VBN	injected	injected	inject	N	O
only	RB	only	only	onli	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
plaque	NN	plaque	plaque	plaqu	N	O
and	CC	and	and	and	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
injecting	VBG	injecting	injecting	inject	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
urethra	NN	urethra	urethra	urethra	N	O
,	,	,	,	,	N	O
nerves	NNS	nerves	nerve	nerv	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
vessels	NNS	vessels	vessel	vessel	N	O
,	,	,	,	,	N	O
corpora	NNS	corpora	corpus	corpora	N	O
cavernosa	VBP	cavernosa	cavernosa	cavernosa	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
collagen	NN	collagen	collagen	collagen	N	O
-	:	-	-	-	N	O
containing	VBG	containing	containing	contain	N	O
structures	NNS	structures	structure	structur	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
penis	NN	penis	penis	peni	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
XIAFLEX	JJ	xiaflex	xiaflex	xiaflex	N	O
REMS	NNP	rems	rem	rem	N	O
Program	NNP	program	program	program	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
corporal	JJ	corporal	corporal	corpor	N	O
rupture	NN	rupture	rupture	ruptur	N	O
(	(	(	(	(	N	O
penile	JJ	penile	penile	penil	N	O
fracture	NN	fracture	fracture	fractur	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
penile	JJ	penile	penile	penil	N	O
injury	NN	injury	injury	injuri	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
is	VBZ	is	is	is	N	O
available	JJ	available	available	avail	N	O
only	RB	only	only	onli	N	O
through	IN	through	through	through	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
REMS	NNP	rems	rem	rem	N	O
Program	NNP	program	program	program	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Required	JJ	required	required	requir	N	O
components	NNS	components	component	compon	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
REMS	NNP	rems	rem	rem	N	O
Program	NNP	program	program	program	N	O
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O

Prescribers	NNS	prescribers	prescribers	prescrib	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
certified	VBN	certified	certified	certifi	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
program	NN	program	program	program	N	O
by	IN	by	by	by	N	O
enrolling	VBG	enrolling	enrolling	enrol	N	O
and	CC	and	and	and	N	O
completing	VBG	completing	completing	complet	N	O
training	NN	training	training	train	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Healthcare	NNP	healthcare	healthcare	healthcar	N	O
sites	VBZ	sites	site	site	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
certified	VBN	certified	certified	certifi	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
program	NN	program	program	program	N	O
and	CC	and	and	and	N	O
ensure	VB	ensure	ensure	ensur	N	O
that	DT	that	that	that	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
is	VBZ	is	is	is	N	O
only	RB	only	only	onli	N	O
dispensed	VBN	dispensed	dispensed	dispens	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
by	IN	by	by	by	N	O
certified	JJ	certified	certified	certifi	N	O
prescribers	NNS	prescribers	prescribers	prescrib	N	O
.	.	.	.	.	N	O

Further	JJ	further	further	further	N	O
information	NN	information	information	inform	N	O
is	VBZ	is	is	is	N	O
available	JJ	available	available	avail	N	O
at	IN	at	at	at	N	O
www	NN	www	www	www	N	O
.	.	.	.	.	N	O
XIAFLEXREMS	NNP	xiaflexrems	xiaflexrems	xiaflexrem	N	O
.	.	.	.	.	N	O
com	NN	com	com	com	N	O
or	CC	or	or	or	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
313	CD	313	313	313	N	O
-	:	-	-	-	N	O
1235	CD	1235	1235	1235	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
Including	NNP	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
mild	VBN	mild	mild	mild	N	B-Severity
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
)	)	)	)	)	N	O
after	IN	after	after	after	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
associated	JJ	associated	associated	associ	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	O
after	IN	after	after	after	N	O
more	RBR	more	more	more	N	O
XIAFLEX	JJ	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
portions	NNS	portions	portion	portion	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
localized	VBN	localized	localized	local	N	B-AdverseReaction
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
after	IN	after	after	after	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycles	NNS	cycles	cycle	cycl	N	O
(	(	(	(	(	N	O
involving	VBG	involving	involving	involv	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
8	CD	8	8	8	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
injection	NN	injection	injection	inject	Y	O
procedures	NNS	procedures	procedure	procedur	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
associated	VBD	associated	associated	associ	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
after	IN	after	after	after	N	O
each	DT	each	each	each	N	O
injection	NN	injection	injection	inject	Y	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
injections	NNS	injections	injection	inject	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
contains	VBZ	contains	contains	contain	N	O
foreign	JJ	foreign	foreign	foreign	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
to	TO	to	to	to	N	O
XIAFLEX	VB	xiaflex	xiaflex	xiaflex	N	O
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
previous	JJ	previous	previous	previou	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
XIAFLEX	VB	xiaflex	xiaflex	xiaflex	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
developed	VBD	developed	developed	develop	N	O
IgE	NNP	ige	ige	ige	Y	O
-	:	-	-	-	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
proportions	NNS	proportions	proportion	proport	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
titers	NNS	titers	titer	titer	N	O
with	IN	with	with	with	N	O
successive	JJ	successive	successive	success	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

Healthcare	NNP	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
prepared	VBN	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
address	VB	address	address	address	N	O
severe	JJ	severe	severe	sever	N	O
allergic	JJ	allergic	allergic	allerg	N	O
reactions	NNS	reactions	reaction	reaction	N	O
following	VBG	following	following	follow	N	O
XIAFLEX	JJ	xiaflex	xiaflex	xiaflex	N	O
injections	NNS	injections	injection	inject	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Abnormal	NNP	abnormal	abnormal	abnorm	N	O
Coagulation	NNP	coagulation	coagulation	coagul	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Dupuytren	NNP	dupuytren	dupuytren	dupuytren	N	O
's	POS	's	's	's	N	O
contracture	NN	contracture	contracture	contractur	Y	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
70%	CD	70%	70%	70%	N	O
and	CC	and	and	and	N	O
38%	CD	38%	38%	38%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
an	DT	an	an	an	N	O
ecchymosis	NN	ecchymosis	ecchymosis	ecchymosi	Y	B-AdverseReaction
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
controlled	VBD	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
65.5%	CD	65.5%	65.5%	65.5%	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBN	developed	developed	develop	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
14.5%	CD	14.5%	14.5%	14.5%	N	O
developed	VBD	developed	developed	develop	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
ecchymosis	NN	ecchymosis	ecchymosis	ecchymosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
coagulation	NN	coagulation	coagulation	coagul	N	O
(	(	(	(	(	N	O
except	IN	except	except	except	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
aspirin	NN	aspirin	aspirin	aspirin	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
150	CD	150	150	150	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
from	IN	from	from	from	N	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
medications	NNS	medications	medication	medic	N	O
(	(	(	(	(	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
aspirin	NN	aspirin	aspirin	aspirin	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
150	CD	150	150	150	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
within	IN	within	within	within	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
XIAFLEX	NNP	xiaflex	xiaflex	xiaflex	N	O
administration	NN	administration	administration	administr	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
XIAFLEX	NN	xiaflex	xiaflex	xiaflex	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
coagulation	NN	coagulation	coagulation	coagul	N	O
disorders	NNS	disorders	disorder	disord	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
anticoagulants	NNS	anticoagulants	anticoagulant	anticoagul	N	O
(	(	(	(	(	N	O
except	IN	except	except	except	N	O
for	IN	for	for	for	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
aspirin	NN	aspirin	aspirin	aspirin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

